Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act

G. Grabowski Henry (), Margaret Kyle, Richard Mortimer, Genia Long and Noam Kirson
Additional contact information
Margaret Kyle: TSE-R - Toulouse School of Economics - UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse - INRA - Institut National de la Recherche Agronomique - EHESS - École des hautes études en sciences sociales - CNRS - Centre National de la Recherche Scientifique, CRM - Centre de Recherche en Management - UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse - IAE - Institut d'Administration des Entreprises - Toulouse - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. Generic drug usage and challenges to brand-name drugs' patents have increased markedly, resulting in greatly increased cost savings but also potentially reduced incentives for innovators. Congress should review whether Hatch-Waxman is achieving its intended purpose of balancing incentives for generics and innovation. It also should consider whether the law should be amended so that some of its provisions are brought more in line with recently enacted legislation governing approval of so-called biosimilars, or the corollary for biologics of generic competition for small-molecule drugs

Keywords: GOAL (Psychology); "GOAL (Psychology)"; DRUG development; "DRUG development"; UNITED States; "UNITED States"; COST control PATENTS "PHARMACEUTICAL industry; COST control PATENTS "PHARMACEUTICAL industry"; COMPETITION (Economics); "COMPETITION (Economics)"; DRUGS Law & legislation United States; "DRUGS Law & legislation United States"; DRUGS Design; "DRUGS Design"; GENERIC drugs; "GENERIC drugs" (search for similar items in EconPapers)
Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Published in Health Affairs, 2011, 30 (11), pp.2157-2166. ⟨10.1377/hlthaff.2010.0270⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-00738443

DOI: 10.1377/hlthaff.2010.0270

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().